Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,151,024 papers from all fields of science
Search
Sign In
Create Free Account
Solitomab
Known as:
Anti-EpCAM BiTE
A recombinant bispecific monoclonal antibody directed against both CD3 and epithelial cell adhesion molecule (EpCAM) with potential immunomodulating…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Antibodies, Bispecific
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2018
Highly Cited
2018
A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors
M. Kebenko
,
M. Goebeler
,
+14 authors
W. Fiedler
Oncoimmunology
2018
Corpus ID: 52279869
ABSTRACT We assessed the tolerability and antitumor activity of solitomab, a bispecific T-cell engager (BiTE®) antibody construct…
Expand
Review
2017
Review
2017
Recent advances of bispecific antibodies in solid tumors
Shengnan Yu
,
Anping Li
,
+6 authors
Kongming Wu
Journal of Hematology & Oncology
2017
Corpus ID: 21878957
Cancer immunotherapy is the most exciting advancement in cancer therapy. Similar to immune checkpoint blockade and chimeric…
Expand
2016
2016
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
S. Bellone
,
J. Black
,
+11 authors
A. Santin
American Journal of Obstetrics and Gynecology
2016
Corpus ID: 37757836
Review
2016
Review
2016
Harnessing T cells to fight cancer with BiTE® antibody constructs – past developments and future directions
M. Klinger
,
J. Benjamin
,
R. Kischel
,
S. Stienen
,
G. Zugmaier
Immunological Reviews
2016
Corpus ID: 11159041
Bispecific T‐cell engager (BiTE®) antibody constructs represent a novel immunotherapy that bridges cytotoxic T cells to tumor…
Expand
2015
2015
Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy‐resistant ovarian cancer cell lines in vitro and fresh tumor cells ex…
D. English
,
S. Bellone
,
+12 authors
A. Santin
Cancer
2015
Corpus ID: 21306854
Solitomab is a novel, bispecific, single‐chain antibody that targets epithelial cell adhesion molecule (EpCAM) on tumor cells and…
Expand
2015
2015
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro
F. Ferrari
,
S. Bellone
,
+12 authors
A. Santin
Journal of experimental & clinical cancer…
2015
Corpus ID: 255986339
Uterine and ovarian carcinosarcomas (CS) are rare but highly aggressive gynecologic tumors which carry an extremely poor…
Expand
2014
2014
Solitomab, an EpCAM/CD3 bispecific antibody (BiTE®), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo
D. English
,
S. Bellone
,
+6 authors
A. Santin
2014
Corpus ID: 71290671
2014
2014
535 Tumor targeting and tissue distribution of solitomab (AMG 110; anti-EpCAM BiTE®) in human EpCAM-positive tumor bearing mice
F. Warnders
,
S. Waaijer
,
+8 authors
E. Vries
2014
Corpus ID: 76133321
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE